Literature DB >> 22343824

Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease.

John M Ringman1, Giovanni Coppola, David Elashoff, Yaneth Rodriguez-Agudelo, Luis D Medina, Karen Gylys, Jeffrey L Cummings, Greg M Cole.   

Abstract

BACKGROUND/AIMS: Biological markers of utility in tracking Alzheimer's disease (AD) during the presymptomatic prodromal phase are important for prevention studies. Changes in cerebrospinal fluid (CSF) levels of 42-amino-acid β-amyloid (Aβ(42)), total tau protein (t-tau) and phosphorylated tau at residue 181 (p-tau(181)) during this state are incompletely characterized.
METHODS: We measured CSF markers in 13 carriers of familial AD (FAD) mutations that are fully penetrant for causing AD (PSEN1 and APP) and in 5 non-mutation-carrying family members.
RESULTS: Even among the entirely presymptomatic mutation carriers (n = 9), Aβ(42) was diminished (388.7 vs. 618.4 pg/ml, p = 0.004), and t-tau (138.5 vs. 50.5 pg/ml, p = 0.002) and p-tau(181) (71.7 vs. 24.6 pg/ml, p = 0.003) were elevated. There was a negative correlation between Aβ(42) levels and age relative to the family-specific age of dementia diagnosis.
CONCLUSIONS: Our data are consistent with a decline in CSF Aβ(42) levels occurring at least 20 years prior to clinical dementia in FAD.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343824      PMCID: PMC3696356          DOI: 10.1159/000335729

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  26 in total

1.  Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

Authors:  C Hesse; L Rosengren; N Andreasen; P Davidsson; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Neurosci Lett       Date:  2001-01-19       Impact factor: 3.046

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease.

Authors:  Liana G Apostolova; Kristy S Hwang; Luis D Medina; Amity E Green; Meredith N Braskie; Rebecca A Dutton; Jeffrey Lai; Daniel H Geschwind; Jeffrey L Cummings; Paul M Thompson; John M Ringman
Journal:  Dement Geriatr Cogn Disord       Date:  2011-09-23       Impact factor: 2.959

4.  Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

Authors:  R Motter; C Vigo-Pelfrey; D Kholodenko; R Barbour; K Johnson-Wood; D Galasko; L Chang; B Miller; C Clark; R Green
Journal:  Ann Neurol       Date:  1995-10       Impact factor: 10.422

5.  Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type.

Authors:  J C Morris
Journal:  Int Psychogeriatr       Date:  1997       Impact factor: 3.878

6.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease.

Authors:  D Scheuner; C Eckman; M Jensen; X Song; M Citron; N Suzuki; T D Bird; J Hardy; M Hutton; W Kukull; E Larson; E Levy-Lahad; M Viitanen; E Peskind; P Poorkaj; G Schellenberg; R Tanzi; W Wasco; L Lannfelt; D Selkoe; S Younkin
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

7.  Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor.

Authors:  N C Fox; A M Kennedy; R J Harvey; P L Lantos; P K Roques; J Collinge; J Hardy; M Hutton; J M Stevens; E K Warrington; M N Rossor
Journal:  Brain       Date:  1997-03       Impact factor: 13.501

8.  Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.

Authors:  N Andreasen; E Vanmechelen; A Van de Voorde; P Davidsson; C Hesse; S Tarvonen; I Räihä; L Sourander; B Winblad; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

9.  Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene.

Authors:  M Mullan; S Tsuji; T Miki; T Katsuya; S Naruse; K Kaneko; T Shimizu; T Kojima; I Nakano; T Ogihara
Journal:  Neurobiol Aging       Date:  1993 Sep-Oct       Impact factor: 4.673

10.  Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.

Authors:  S O'Riordan; P McMonagle; J C Janssen; N C Fox; M Farrell; J Collinge; M N Rossor; M Hutchinson
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

View more
  13 in total

Review 1.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

2.  Early behavioural changes in familial Alzheimer's disease in the Dominantly Inherited Alzheimer Network.

Authors:  John M Ringman; Li-Jung Liang; Yan Zhou; Sitaram Vangala; Edmond Teng; Sarah Kremen; David Wharton; Alison Goate; Daniel S Marcus; Martin Farlow; Bernardino Ghetti; Eric McDade; Colin L Masters; Richard P Mayeux; Martin Rossor; Stephen Salloway; Peter R Schofield; Jeffrey L Cummings; Virginia Buckles; Randall Bateman; John C Morris
Journal:  Brain       Date:  2015-02-15       Impact factor: 13.501

3.  F-spondin gene transfer improves memory performance and reduces amyloid-β levels in mice.

Authors:  D M Hafez; J Y Huang; J C Richardson; E Masliah; D A Peterson; R A Marr
Journal:  Neuroscience       Date:  2012-07-31       Impact factor: 3.590

Review 4.  Ushering in the study and treatment of preclinical Alzheimer disease.

Authors:  Jessica B Langbaum; Adam S Fleisher; Kewei Chen; Napatkamon Ayutyanont; Francisco Lopera; Yakeel T Quiroz; Richard J Caselli; Pierre N Tariot; Eric M Reiman
Journal:  Nat Rev Neurol       Date:  2013-06-11       Impact factor: 42.937

5.  Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.

Authors:  Eric M Reiman; Yakeel T Quiroz; Adam S Fleisher; Kewei Chen; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Anne M Fagan; Aarti R Shah; Sergio Alvarez; Andrés Arbelaez; Margarita Giraldo; Natalia Acosta-Baena; Reisa A Sperling; Brad Dickerson; Chantal E Stern; Victoria Tirado; Claudia Munoz; Rebecca A Reiman; Matthew J Huentelman; Gene E Alexander; Jessica B S Langbaum; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera
Journal:  Lancet Neurol       Date:  2012-11-06       Impact factor: 44.182

Review 6.  Fluid biomarkers in Alzheimer's disease - current concepts.

Authors:  Christoffer Rosén; Oskar Hansson; Kaj Blennow; Henrik Zetterberg
Journal:  Mol Neurodegener       Date:  2013-06-21       Impact factor: 14.195

Review 7.  Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.

Authors:  Suzanne Elizabeth Schindler; Anne M Fagan
Journal:  Front Neurol       Date:  2015-06-29       Impact factor: 4.003

8.  Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers.

Authors:  John M Ringman; Jennifer L Tomic; Giovanni Coppola; David Elashoff; Karen H Gylys; Charles G Glabe
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-12-15

9.  Metabolic profiling of Alzheimer's disease brains.

Authors:  Koichi Inoue; Haruhito Tsutsui; Hiroyasu Akatsu; Yoshio Hashizume; Noriyuki Matsukawa; Takayuki Yamamoto; Toshimasa Toyo'oka
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

Review 10.  Alzheimer's disease: Unique markers for diagnosis & new treatment modalities.

Authors:  Neelum T Aggarwal; Raj C Shah; David A Bennett
Journal:  Indian J Med Res       Date:  2015-10       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.